

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CANbridge Pharmaceuticals Inc.
北海康成製藥有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1228)

**POLL RESULTS OF THE EXTRAORDINARY GENERAL MEETING
HELD ON DECEMBER 4, 2025**

The Board hereby announces that all resolutions set out in the EGM Notice were duly passed by the Shareholders by way of a poll at the EGM held on Thursday, December 4, 2025.

EXTRAORDINARY GENERAL MEETING (THE “EGM”)

Reference is made to the circular (the “**EGM Circular**”) and the notice of the EGM (the “**EGM Notice**”) of CANbridge Pharmaceuticals Inc. (the “**Company**”) both dated November 19, 2025. Unless the context otherwise requires, capitalized terms used herein shall have the same meanings as those defined in the EGM Circular.

POLL RESULTS OF EGM

The Board is pleased to announce that all of the proposed resolutions as set out in the EGM Notice were duly passed by the Shareholders as ordinary resolutions by way of poll at the EGM held on Thursday, December 4, 2025. The poll results in respect of the resolutions passed at the EGM are as follows:

ORDINARY RESOLUTIONS		NO. OF VOTES (%)	
		For	Against
1.	To grant a new general mandate to the directors of the Company (the “ Directors ”) to allot and issue shares of the Company (the “ Shares ”) not exceeding 20% of the Company’s issued share capital as at the date of passing the relevant resolution at the EGM (excluding any Shares held in treasury).	143,690,478 (100%)	0 (0%)
2.	To extend the new general mandate to Shares repurchased by the Company pursuant to the repurchase mandate granted to the Directors at the annual general meeting of the Company held on June 27, 2025.	143,690,478 (100%)	0 (0%)

Please refer to the EGM Notice for the full text of the resolutions above.

As more than 50% were casted in favour of each of the above ordinary resolutions numbered 1 and 2, all of the above ordinary resolutions were duly passed as ordinary resolutions of the Company.

GENERAL

As of the date of the EGM, a total of 510,826,484 Shares were in issue. Dr. Xue, being an executive Director, together with his associates (including CTX Pharma Holdings Limited and the Family Trust), who held 41,881,521 Shares as at the date of the EGM (representing approximately 8.20% of the issued share capital as at the date of the EGM), were required under the Listing Rules to abstain, and did abstain, from voting in favour of the resolutions numbered 1 and 2 proposed at the EGM. Accordingly, the total number of Shares entitling the holders to attend and vote for or against the resolutions numbered 1 and 2 proposed at the EGM was 468,944,963 Shares.

Save as disclosed above, to the best knowledge, belief and information of the Directors having made all reasonable enquiries, (i) there were no Shares entitling the holder to attend and abstain from voting in favour of any resolutions proposed at the EGM as set out in Rule 13.40 of the Listing Rules, (ii) there was no restriction on any Shareholders to cast votes on any of the resolutions proposed at the EGM, (iii) no Shareholders were required to abstain from voting at the EGM under the Listing Rules, and (iv) none of the Shareholders has stated their intention in the EGM Circular to vote against or to abstain from voting on any of the resolutions proposed at the EGM.

The Company's share registrar in Hong Kong, Computershare Hong Kong Investor Services Limited, was appointed as the scrutineer at the EGM for the purpose of vote-taking. Six of the seven Directors, namely Ms. Wei Zhao, Mr. Tingwei Wang, Dr. Richard James Gregory, Mr. James Arthur Geraghty, Mr. Peng Kuan Chan and Dr. Lan Hu, attended the EGM.

By Order of the Board
CANbridge Pharmaceuticals Inc.
Dr. James Qun Xue
Chairman

Hong Kong, December 4, 2025

As of the date of this announcement, the Board comprises Dr. James Qun Xue as executive Director; Ms. Wei Zhao and Mr. Tingwei Wang as non-executive Directors; and Dr. Richard James Gregory, Mr. James Arthur Geraghty, Mr. Peng Kuan Chan and Dr. Lan Hu as independent non-executive Directors.